Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer

• Auteurs principaux: Paul M. Kuhn (Auteur), Gabriella C. Russo (Auteur), Ashleigh J. Crawford (Auteur), Aditya Venkatraman (Auteur), Nanlan Yang (Auteur), Bartholomew A. Starich (Auteur), Zachary Schneiderman (Auteur), Pei-Hsun Wu (Auteur), Thi Vo (Auteur), Denis Wirtz (Auteur), Efrosini Kokkoli (Auteur)
• Format: Livre
• Publié: MDPI AG, 2024-07-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Effectively utilizing MEK inhibitors in the clinic remains challenging due to off-target toxicity and lack of predictive biomarkers. Recent findings propose E-cadherin, a breast cancer diagnostic indicator, as a predictor of MEK inhibitor success. To address MEK inhibitor toxicity, traditional metho...